How many drugs treat Hypophosphatemia?

Drug Landscape tracks 4 marketed treatments for Hypophosphatemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hypophosphatemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hypophosphatemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypophosphatemia (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypophosphatemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Perikabiven In Plastic Container	SODIUM GLYCEROPHOSPHATE	Fresenius Kabi			2014-01-01
Osmoprep	sodium phosphate, monobasic, monohydrate	Salix Pharms	Calculi Dissolution Agent [EPC]		2000-01-01
Calcijex	CALCITRIOL	Esjay Pharma	Vitamin D3 Analog [EPC]	Vitamin D3 receptor	1978-01-01
Rocaltrol	Rocaltrol	Shandong University		Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Hypophosphatemia
Esjay Pharma · 1 drug in Hypophosphatemia
Fresenius Kabi · 1 drug in Hypophosphatemia
Salix Pharms · 1 drug in Hypophosphatemia
Shandong University · 1 drug in Hypophosphatemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypophosphatemia:

Cite this brief

Drug Landscape (2026). Hypophosphatemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypophosphatemia. Accessed 2026-06-10.

Hypophosphatemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing